CPT® Code 81207

The CPT® Code 81207 pertains to the molecular genetic testing aimed at identifying a specific mutation of the BCR/ABL1 gene, which is frequently associated with chronic myelogenous leukemia (CML). This mutation is characterized by a reciprocal translocation, denoted as t(9;22), which involves the BCR gene located on chromosome 22, commonly referred to as the Philadelphia chromosome, and the ABL1 gene situated on chromosome 9. The resultant fusion gene from this translocation encodes a tyrosine kinase that is unregulated and targets the cytoplasm, facilitating cell proliferation without the normal regulatory influence of cytokines. This unregulated growth predisposes individuals to certain types of cancers, particularly CML. Molecular testing, including techniques such as reverse transcription polymerase chain reaction (rtPCR) or fluorescence in situ hybridization (FISH), is essential at the initial diagnosis of CML. These tests help define tumor markers that are crucial for measuring residual disease during and after treatment. The BCR gene is known to have three distinct breakpoint cluster regions, which are critical for accurate diagnosis and treatment monitoring. For instance, CPT® Code 81206 is used for identifying the major breakpoint at p210, which occurs in the major breakpoint cluster region (M-bcr) around exon b3, leading to the formation of the BCR-ABL1 p210 chimeric transcript. In contrast, CPT® Code 81207 is specifically designated for the identification of the minor breakpoint at p190, which occurs in the minor breakpoint cluster region (m-bcr) on intron 1, resulting in the fusion of BCR exon 1 with the same ABL1 exons. Additionally, CPT® Code 81208 is available for identifying other breakpoint cluster regions that are not classified as major or minor. This structured approach to genetic testing is vital for the effective management and treatment of patients diagnosed with CML.